BUSINESS HOPE IN A BOTTLE Antigenics will find out within weeks just how effectively its vaccine is helping patients with kidney cancer live longer.
BODY, HEAL THYSELF After false starts, cancer immunotherapies tiptoe toward commercialization LISA M. JARVIS, C&EN NORTHEAST NEWS BUREAU
A
T A PANEL DISCUSSION AT THE
Biotechnology Industry Organization's annual CEO & Investor Conference last month, the presenters couldn't resist commenting on the tide oftheir session: "Cancer Immunotherapies Corning ofAge." Peter Working, senior vice president of R&D at Cell Genesys, went soferas to thank the moderator for ending the sentence in a period, rather than a question mark. The point was well-taken. Once hyped as the next big thing in the biotechnology business, cancer immunotherapy companies have fallen off the radar of the investment community. Their lofty stock prices of five years ago have come down to earth, and some industry observers wonder whether the technology can ever live up to expectations. The theory underlying therapeutic cancer vaccines appears sound. Vaccines have traditionally been used as preventive measures; they teach the immune system how to make the antibodies it will need to fight a disease so that it is prepared for future battles. Companies pursuing therapeutic vaccines, also called active immunotherapies, believe the immune system can learn how to ward off a disease even after it has already taken hold. No therapeutic cancer vaccines have WWW.CEN-0NLINE.ORG
made it to market, and several high-profile, late-stage development failures have reinforced the naysayers' convictions that they don't work. Just last year, Philadelphia-based Aphton said its cancer vaccine Insegnia did not prevent tumor growth or lengthen the life of patients with pancreatic cancer, and Carlsbad, Calif-based CancerVax dropped its cancer immunotherapy Canvaxin from development after disappointing results in Phase III studies in advanced melanoma. Despite these setbacks, cancer vaccine companies are optimistic that their technology is poised to come into its own, and they believe that 2006 could be a big year in terms ofproof of concept. Companies point to the long roller-coaster ride that almost all new technologies must endure before achieving a true breakthrough, drawing a parallel with the tumultuous decades that preceded the launch of the first therapeutic monoclonal antibodies. "That cycle of hyperbole and unreasonable rejection and disappointment and more measured success is unfortunately long, 15 to 20 years," says Steven A. Sherwin, chairman and chief executive officer of Cell Genesys. Sherwin should know. When he was at the National Cancer Institute, he conducted the first trial of a monoclonal antibody in a
cancer patient and rode through that cycle before finally seeing success. In the late 1980s, he says, "the press was talking about monoclonal antibodies as magic bullets for cancer." Those early MAbs, however, were mouse antibodies and produced allergic reactions in humans. Thus, they showed only limited efficacy in treating disease. In the antibody space, the critical breakthrough came when technology evolved to enable the production of humanized antibodies. Ten years after the media frenzy over MAbs, several billion-dollar products are on the market. The analogy with the development of MAbs is good, says Thomas B. Okarma, president and CEO of Geron, because many cancer immunotherapies that have gone through and failed late-stage trials have been based on old technology. "Immunotherapy against cancer is not simple," Okarma explains. Cancer immunotherapies, he notes, must overcome two critical hurdles. First, cancer patients by definition are immunocompromised, which means vaccines must work extra hard to generate an adequate immune response. Second, such therapies must also break the body's tolerance of its own antigens, the proteins or other substances that stimulate an immune response. ANOTHER MAJOR hurdle has been designing clinical trials that will appropriately measure the success of an immunotherapy. Traditionally, cancer patients have been treated with cytotoxic agents, which upon entering the body, immediately start killing rapidly dividing cells, both the sick and the healthy. This approach produces a measurable result, such as tumor shrinkage, after a well-defined treatment period. Using that same yardstick in a trial for a cancer immunotherapy will inevitably lead to failure, says Garo H. Armen, president and CEO of cancer vaccine developer Antigenics. "Priming the immune system takes time," he notes, and teaching it to recognize and destroy cancer can take months. "The traditional end point is not going to work," agrees Fleur Pijpers, oncology analyst at the health care consulting firm Datamonitor. Monitoring the immune response would be a valuable clinical end point for companies, she notes, but good methods of measuring that response across multiple tumor types have yet to be developed. The natural learning curve that the imC & E N / MARCH 2 7 , 2006
23
BUSINESS mune system must navigate means that has become crowded with cancer immunocancer immunotherapies are unlikely to therapies. Datamonitor found at least 64 be successful in patients with late-stage companies active in the space that offer a cancers. Yet the traditional approach with huge range of approaches to teaching the new cancer drugs has been to initiate trials immune system to combat cancer. in the sickest patients. Companies develThe products that have made it to lateoping cancer vaccines are now figuring out stage trials can be broken down into three that they need to choose patient populations general categories: patient-specific vaccines, with a better survival outlook in order to which are made from the patient's own show efficacy. The body's learning curve leads ON THE BRINK to yet another hurdle: determinSeveral cancer immunotherapies are now in ing just how many months it takes Phase III trials for the immune system to start to
general component, prostatic acid phosphatase, a recombinant protein found in 95% of prostate cancers. The dendritic cells, now loaded with the antigen, are then injected back into the patient to trigger a reaction from the immune system. Patients receive three doses of the vaccine over the course of a month. The method appears to be offering patients some hope. The combined data from two Phase III trials in androgen-independent patients showed that the vaccine extended survival by four months, a 23% improvement over a placebo. And just combat cancer on its own. W i t h COMPANY TYPE PRODUCT over twice as many patients given few precedents to follow, compaPatient specific Antigenics Oncophaqe the vaccine (33%) compared with nies have had to figure out a dosAntigen specific Aphton IGN101 those given a placebo (15%) were still ing regimen and whether to give Antigen specific Biomira/Merck KGaA L-BLP25 alive 36 months after treatment. booster shots to keep the immune Patient specific Biovest/Accentia Biovaxid system on track. Dendreon has also completed Cell Genesys Whole cell GVax It is also unclear whether a enrollment in a Phase III trial in Patient specific Dendreon Provenge cancer vaccine will ever actually patients with the earlier stage and Patient specific Favrille Favld induce tumor shrinkage or, as milder androgen-dependent prostate Patient specific Genitope MyVax many believe is more likely, only cancer. "The idea is that Provenge Medarex/BristolAntigen specific keep the tumor from growing so would be most effective when the Myers Squibb MDX-1379 Antigen specific Progenies GMK that a patient can essentially live tumor burden is the smallest," Urdal Antigen specific Therion Biologies Panvac-VF with the cancer indefinitely. As notes. There has also been evidence they are doing with the newer that administering the vaccine prior SOURCES: Datamonitor, companies monoclonal antibody drugs, canto chemotherapy rather than after it cer vaccine companies are genermight be an effective sequence. ally measuring their product's ability to As the first player to ask FDA for approvtumor; whole-cell vaccines, which address prolong survival rather than its impact al for a cancer immunotherapy, Dendreon a wide range of antigens; and antigen-specould be facing a tough advisory panel. The on tumor size. cific vaccines, which target one particular company must be armed with the data to adDespite the complexity of teaching the antigen that is believed to be responsible for dress the slew of new issues related to clinibody to, in essence, heal itself, companies are cancer growth. The first method creates a cal trial design and manufacturing. "When confident that they have managed to overpersonalized vaccine, whereas the latter two you're in the lead, you're marching, but you come most of the hurdles. At least 12 cancer generate off-the-shelf vaccines that can be also have a lot of arrows in your back," Urdal immunotherapies are in Phase III trials and used on the general population. acknowledges. dozens more are in Phases I and II. Seattle-based Dendreon, with its perOn the other hand, there is also the po"Ifyou look at where vaccines are today, sonalized approach, is widely viewed as tential for an enormous upside, he points we have very substantial, good results in the front-runner in the race to get a cancer out. Being first to market not only allows Phase II trials with a variety of different vaccine to the market. The company is a company to capture market share, but it therapeutic vaccines," says Alex McPherson, preparing a Biologies License Application also means setting the standard for other president and CEO of Biomira. He points (BLA) for Provenge, which has been granted cancer immunotherapy companies to meet out that some analysts expect the cancer fast-track status by the Food & Drug Ador beat. Needham & Co. stock analyst Mark immunotherapy market to be worth $6 ministration for use in men with metastatic, Monane says that in the U.S. alone, roughly billion by 2010. androgen-independent prostate cancer. 100,000 prostate cancer patients could Datamonitor has come up with the less Provenge is in a sense both personalized heady figure of $600 million in therapeutic and general, says David L. Urdal, Dendreon's benefit from Provenge. He expects it to be launched in mid-2007 and to hit peak sales cancer vaccine sales in 2010. However, alchief scientific officer and vice chairman. of$l billion in 2012. though she is cautious about the near-term The personalized component comes from a Dendreon has, in a sense, a hybrid of a prospects, Pijpers believes that as technolblood sample taken from a patient in order personalized and general vaccine, whereas ogy evolves, significant commercial breakto isolate dendritic cells, which deliver antithroughs could easily raise that forecast. gens to T-cells and B-cells, the lymphocytes New York City-based Antigenics is taking a purely personalized approach. The comRegardless of the current lack of comthat control the immune response. Those pany's lead candidate, Oncophage, is made mercial success, the developmental pipeline dendritic cells are then cultured with the
Companies developing cancer vaccines are now figuring out that they need to choose patient populations with a better survival outlook to show efficacy. 24
C & E N / MARCH 27, 2006
WWW.CEN-0NLINE.ORG
It's time to get promoted. Aerotek Scientific is your personal advocate to find that perfect fit. More than just recruiters, we are promoters and believers in your abilities. Call now, and let's get to work. Technical Recruiting.
Offices Nationwide.
888-AEROTEK
www.aerotek.com
Aerotek Scientific LLC is a subsidiary of Aerotek, Inc.
•feat
I was impressed w i t h my A e r o t e k recruiter. She worker f o r me a n d g o t my resume t o t h e r i g h t person. She knows this industry a n d f o u n d t h e j o b t h a t fits me perfectly.
EB-gHma •EH MEMBER
People. Fit. Perfectly.'
Aerotek is an equal opportunity
employer. An Allegis Group Company. © 2006 Request more at AdlnfoNow.org
American Staffing Association
BUSINESS entirely from the patient's own tumor in order to tap into cellular regulatory components called heat-shock protein-peptide complexes. Inside a healthy cell, heat-shock proteins (HSPs) are worker bees, helping to fold proteins and to chaperone abnormal peptides out of the cell. But when HSPs themselves are found outside a cell, it is a flag that the cell is dead and triggers an immune response against the disease or infection that killed the cell.
Antigenics tries to mimic flags unique to each patient by isolating from their tumor an HSP called gp96 and the peptides associated with it, then returning the HSP-peptide complexes to the patient to stimulate the immune system to target those specific cancer cells. Patients receive a 12-dose regimen of the vaccine, getting one shot per week for a month, then every two weeks for two months. Antigenics will soon find out just how powerful this personalized approach can be.
gg^^.HHSMttWfci, O-MDTHEANSWE allenge w ; Find an icient route for the synthesis cl isolation of an indanol derivative, warded December, 2003. Solver: Post-Doctoral Researcher, Shanghai, China
Can you solve this Challenge?]!
INNOCENTIVE 3327217 Catalyst system for the synthesis of a monoresorcinyl triazine DEADLINE: JULY 2006 $50,000 USD
InnoCentive is a dynamic Web-based community that matches top scientists to relevant research and development challenges facing leading companies around the globe, for rewards up to $100,000 USD. More than 90,000 scientists worldwide have already registered and solved dozens of Challenges. Join them today, and find your own answers.
INNOCENTIVE' Find dozens of chemistry and biology Challenges now at www.innocentive.com. ©2006 InnoCentive, Inc. All rights reserved. InnoCentive and the InnoCentive logo are registered trademarks and InnoCentive Challenge is a trademark of InnoCentive, Inc.
Thefinalresultsfromits Phase III trial of Oncophage in kidney cancer are expected to be unveiled sometime in April. At that stage, assuming positive data, Antigenics will discuss with FDA the best path forward to gain marketing approval. There are limitations to Antigenics' approach. The patient's tumor must be both operable and sufficiently large to enable the production of the vaccine, conditions that could limit the types of cancer that the treatment can address. Furthermore, significant challenges in maintaining sterility conditions are associated with transporting a tumor sample after surgery to the company's facility in Lexington, Mass., and then back to the patient, not to mention the cost of an individualized product. "NO QUESTION that making something that's customized is more onerous than making something off-the-shelf," Armen says. However, he points out that Oncophage's manufacturing process does not involve growing cell culture, which significantly lowers thefixedcosts of making the vaccine. Armen expects Oncophage to be priced similarly to the monoclonal antibodies that are currently marketed for cancer. If Antigenics is offering the customization of a Bentley, technologyfromEdmonton, Alberta-based Biomira enables the assembly-line approach of the Model T Ford. Biomira's vaccine targets a specific antigen that is overexpressed in specific tumor types but in the package of a generalized vaccine that the company says is less expensive to manufacture. The company's liposome-based vaccine technology involves embedding in an artificial membrane both a tumor-specific antigen and an immune-system-stimulating molecule that acts as an adjuvant. Given separately, the antigen and adjuvant are not potent enough to provoke the immune system, "but as soon as you put them together into the housing of the liposome, you see a massive response," says Peter Emtage, Biomira's vice president for R&D and technical operations. The most advanced liposomal vaccine to come out of the company's program is L-BLP25, which targets MUC1, a protein found on the surface of non-small-cell lung cancer (NSCLC) cells. Preliminary data from a Phase lib trial showed that the vaccine was able to extend average survival in NSCLC patients to 30.6 months, compared with 133 months for the unvaccinated group. InJanuary, Biomira licensed L-BLP25 to Merck KGaA of Germany. Merck took all financial and developmental responsibility
Request more at AdlnfoNow.org 26
C & E N / MARCH 2 7, 2006
WWW.CEN-0NLINE.ORG
Aminosugar Syntons for the vaccine, including executing a Phase III trial in lung cancer, expected to begin enrollment later this year. Meanwhile, rather than using a single agent from within the cell as Biomira does, South San Francisco-based Cell Genesys believes that using whole cells is the key to evoking a strong enough immune response to actually affect patient survival. "Tumors change while they grow," Sher-
macrophage colony-stimulating factor (GMCSF), a hormone that jump-starts the immune system's ability to recognize and kill cancer cells. The product is then irradiated to make it safe to be given to patients.
THE MOST ADVANCED studies of GVax are in prostate cancer, with two Phase III trials comparing it with Sanofi-Aventis' Taxotere, the current standard of care. Phase II studies showed that the product extended average patient survival by roughly seven months compared with the published median survival time for Taxotere. Cell Genesys is also conducting two Phase II trials to test whether GVax can keep cancer from recurring in patients in remission. GVax is given to pancreatic cancer patients after they have undergone surgery to remove their tumors and have completed radiation therapy. From a manufacturing standpoint, whole-cell vaccines may be the most difficult to produce. "It is new ground, and it is challenging," Sherwin acknowledges. But confident that it can tackle the problem, Cell Genesys has invested in a commercial-launch facility in Hayward, Calif. With companies taking a range of approaches to coaxing the immune system into attacking cancer cells, the biopharmaceutical industry PROPOSED MECHANISM After Cell Genesys's GVax is is still waiting to see which injected into a patient with prostate cancer, granulocyte- vaccine method—personalized, antigen-specific, or macrophage colony-stimulating factor secreted by whole-cell—will be most genetically modified tumor cells in the vaccine (light spots) activates the immune system (dotted circles) to successful. Each category could produce marketed respond to the cancer cells (dark spots). products within the next two to five years, a clear sign that the techwin, the CEO, explains. "If you pick one nology has come a long way. antigen and it mutates off the cancer cell or gets physically shed, then your immunoStill, some industry observers believe therapy has produced an immune response that yet another generation of technology against a molecule that is no longer on the could prove much more powerful. Each tumor cell." of the current approaches has one or even Like Dendreon's Provenge, Cell Genesys' multiple limitations—from manufacturing main product, GVax, works by activating challenges, to the type of tumors that can dendritic cells. But instead of harvesting be addressed, to the ability to evoke a strong those cells from the patient's blood as Denenough immune response. dreon does, Cell Genesys has devised an off"We think the way forward would be the-shelf product by genetically modifying for different companies to get together whole tumor cells to secrete granulocyteand combine forces," Datamonitor's Pijpers
for Oligosaccharides Syntheses (mtomSymiv,%is oi'v LUemicms Fine & Specialty Chemicals
pir^o OMP
Bn
NPhth 4-Methoxyphenyl 3-O-Benzyl4,6-0-benzylidene-2-deoxy2-phthalimido-p-D-glucopyranoside CAS# 129575-88-8 [Ml 609]
^ GAGs Glycolipids Glycopeptides
PhT-0 0 HO
Ph
OMP
N, 4-Methoxyphenyl 2-Azido4,6-0-benzylidene-2-deoxyp-D-glucopyranoside [Ml 637]
OMP
All
N3 4-Methoxyphenyl 3-0-Allyl-2-azido4,6-0-benzylidene-2-deoxyp-D-galactopyranoside ^ [Ml 643] ^
O-Linked Glycopeptides A/-Linked Ac Ac
OAc 0 N3 NHAc
2-Acetamido-3/4/6-tri-0-acetyl2-deoxy-p-D-glucopyranosyl Azide CAS# 6205-69-2 [A1616]
Also, ask us for other Sugar Syntons.
TCI AMERICA 800-423-8616 •503-283-1681 Fax 888-520-1075 •503-283-1987
[email protected] www.tciamerica.com Head Office: TOKYO CHEMICAL INDUSTRY CO., LTD. (Formerly Tokyo Kasei Kogyo Co., Ltd.) www.tokyokasei.co.jp Request more at AdlnfoNow.org
WWW.CEN-0NLINE.ORG
C & E N / MARCH 2 7 , 2006
27
BUSINESS notes. For example, it would make sense for a company with a great adjuvant to pair with another company with a vaccine that targets multiple antigens. So far, there is little evidence that companies are ready to team up. The closest example comes from Menlo Park, Calif-based Geron, which, in what some would view as the ultimate validation of its technology, is collaborating with the big pharma company Merck & Co. to develop a vaccine targeting telomerase, an enzyme that plays an instrumental role in immortalizing cancer cells. The nine-month-old deal will leverage both companies' immunization platforms against Geron's telomerase target. Merck uses adenoviruses and plasmids to target telomerase, and Geron uses dendritic cells. The collaboration enables the companies to compare their platforms in animal models and could lead to a combined approach that would elicit the most powerful immune response. ON ITS OWN, Geron's technology has already shown promise in the clinic. The company uses the patient's own dendritic cells to generate T-cells against the telomerase.
Telomerase is a particularly intriguing target because it is a universal antigen—all cancers depend on it—yet it is not found in most normal cells and tissues, Okarma says. Geron's technology also activates the dendritic cells in such away that the T-cells attacking telomerase are generated regardless of a patient's tissue type. The end result is a universal antigen that can be used for patients of all tissue types, Okarma says. Geron has validated the approach in Phase I/II clinical trials in prostate cancer patients. The vaccine induced an extraordinary immune response, Okarma notes, showing the vaccine's ability to break tolerance in cancer patients. Furthermore, the level of prostate-specific antigen—the marker of disease progression in prostate cancer—was reduced or eliminated after vaccination. That result shows that the Tcells being induced are actually killing the cancer cells. Despite the positive results, Okarma acknowledges the drawbacks of Geron's current technology. Like Dendreon, Geron is using patient-specific dendritic cells. A blood sample is taken from a patient, pulsed with RNA for the telomerase protein component, and
then injected back into the patient. Though Geron has made strides to reduce the cost of the vaccine, "it will always be more expensive than a vaccine made in multidose production lots," Okarma says. To address this limitation, the company is now developing a technology platform that uses embryonic stem cells that are charged with telomerase to generate general vaccines that behave like the patient-specific vaccines. Stem cell production "is really going to change the landscape in cancer immunotherapy," Okarma says. "You've then used modern immunology infused with modern tumor biology to create a powerful generic platform. I think then you'll really be at a point when the technology has come of age." For cancer vaccines, the cycle of hyperbole, disappointment, and success now appears closer to the end than to the beginning. Okarma believes his stem cell plan could be less than three years away, and several other vaccines are poised to test the waters before then. "There will be more failure, but I am absolutely confident there will be success," Sherwin says. "It only takes one success to wipe away years of skepticism." •
MAYBRÏDGE1
Skip some steps Our structurally and chemically diverse building blocks literally allow you to skip some steps. They allow you to concentrate on the production of lead compounds rather than spending time building starting materials. Maybridge has spent over 40 years synthesizing novel heterocycles. Our skill and expertise with medicinal chemistry can be used to give you the leading edge. At Maybridge, we offer a diverse range of building blocks designed for hit generation and hit-to-lead programs, as well as screening libraries, and custom services. Maybridge pic Trevillet, Tintagel, Cornwall PL34 OHW, England Telephone +44 (0)1-866-205-3502 Fax +44 (0)1-840-770-111
What else do we offer? Trust. No strings attached, ever. And our products and our confidentiality is assured. Now that you've discovered Maybridge, may your next discovery be right around the corner. To learn more about Maybridge products and services and to register to receive new product updates, visit our newly designed website.
Web www.maybridge.com
Email
[email protected] Request more at AdlnfoNow.org 28
C&EN / MARCH 27, 2006
WWW.CEN-0NLINE.ORG
